The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial

For the treatment of metastatic renal cell cancer several strategies are used among which the mTOR inhibitor everolimus. As mTOR plays an important role in the immune system, e.g., by controlling the expression of the transcription factor FoxP3 thereby regulating regulatory T cells (Tregs), it plays...

Descripción completa

Detalles Bibliográficos
Autores principales: Huijts, Charlotte M., Lougheed, Sinéad M., Bodalal, Zuhir, van Herpen, Carla M., Hamberg, Paul, Tascilar, Metin, Haanen, John B., Verheul, Henk M., de Gruijl, Tanja D., van der Vliet, Hans J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426984/
https://www.ncbi.nlm.nih.gov/pubmed/30652208
http://dx.doi.org/10.1007/s00262-018-2288-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426984/
https://www.ncbi.nlm.nih.gov/pubmed/30652208
http://dx.doi.org/10.1007/s00262-018-2288-8

Ejemplares similares